Aldeyra One Step Closer To Joint Treatment For Allergic Conjunctivitis, Dry Eye Disease
Executive Summary
With Phase III programs on similar timelines, Aldeyra hopes it may be able to file for both indications concurrently for its aldehyde trap candidate reproxalap.
You may also be interested in...
Aldeyra Allergic Conjunctivitis Drug Has Good Prospects With Phase III Results
The company announced positive results for reproxalap from its Phase III INVIGORATE trial in allergic conjunctivitis, which may be a good sign for its dry eye disease studies.
Five Phase III Data Readouts To Look Out For In Q2
Phase III trials of a number of late-stage investigational therapies are expected to read out during the second quarter of 2021, according to new analysis from Informa Pharma’s product pipeline database Biomedtracker. Some of the Phase III data could be transforming for a few of the less grand players in the pharma sector and here Scrip picks out some of the highlights to look out for in the months ahead.
Finance Watch: Genfit Launches IPO To Expand US Presence Ahead Of Phase III NASH Results
Public Company Edition: COO Dean Hum talked to Scrip about Genfit's IPO strategy – which wasn't just about raising money – as it anticipates Phase III elafibranor data later this year. Also, Precision BioSciences launches its IPO, while Myokardia, Dermira and Tricida lead new public company financings.